Vestal Point Capital, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001974915

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q2 2024 · 60 positions · Total reported value $1.34B · Top-10 concentration 54.9% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 64.6% · 14 new · 20 cut · 19 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.4% · vs SPY -15.5% · Prev Value $4.28B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -2.9% · vs SPY -5.1% · Latest Value $3.87B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2024 13F filing, Vestal Point Capital, LP disclosed 60 equity positions with a combined reported value of $1.34B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 54.9% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2024 were JAZZ ($160.09M), CYTK ($112.42M), ASND ($102.28M). By sector, the heaviest allocations are Health Care 78.1%, Other 21.9%. Versus the prior quarter, allocation shifted toward Other (+4.3pp) and away from Health Care (-3.9pp).

Versus the prior quarter, Vestal Point Capital, LP opened 14 new positions, trimmed 20 and fully exited 19, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 49% of names.

The largest new positions opened in Q2 2024 were JANX ($30.37M), SVRA ($26.15M), ITOS ($25.97M).

Of the 19 positions fully exited versus the prior quarter, the largest were NBIX ($97.92M), ALNY ($52.31M), AZN ($27.10M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2024)

  • JANX JANUX THERAPEUTICS INC · $30.37M
  • SVRA SAVARA INC · $26.15M
  • ITOS ITEOS THERAPEUTICS INC · $25.97M
  • AXSM AXSOME THERAPEUTICS INC. · $24.15M
  • GPCR STRUCTURE THERAPEUTICS INC · $21.99M
  • BMY BRISTOL-MYERS SQUIBB CO · $20.77M
  • DAWN DAY ONE BIOPHARMACEUTICALS I · $17.23M
  • IMNM IMMUNOME INC · $12.10M

Fully Exited (vs previous quarter)

  • NBIX NEUROCRINE BIOSCIENCES INC · prev qtr: $97.92M · history
  • ALNY ALNYLAM PHARMACEUTICALS INC · prev qtr: $52.31M
  • AZN ASTRAZENECA PLC · prev qtr: $27.10M
  • ARGX ARGENX SE · prev qtr: $19.69M
  • TGTX TG THERAPEUTICS INC · prev qtr: $15.97M
  • BMRN BIOMARIN PHARMACEUTICAL INC · prev qtr: $15.28M · history
  • ALPN ALPINE IMMUNE SCIENCES INC · prev qtr: $13.87M
  • SRPT SAREPTA THERAPEUTICS INC · prev qtr: $12.95M

Insider Transactions (Form 4)

Latest Vestal Point Capital, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Vestal Point Capital, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 63 US equity positions with a combined value of $3.87B. HoldingsHub carries 12 quarters of its filings (Q4 2023–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-127682 (status: Approved), registered 2023-04-14
  • Regulatory AUM (Form ADV): $5.47B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds
  • Website: vestalpoint.com

Portfolio Structure

  • 63 positions · $3.87B reported value (Q3 2026)
  • Top 10 holdings = 67.3% of reported value
  • Largest position: ABVX (ABIVAX SA) at 10.1%
  • Average position size: $61.44M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 14 new, 22 added, 20 reduced, 19 exited
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 78.1%
Other 21.9%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.50M $160.09M 11.94%
11.94%
Add
2 2.08M $112.42M 8.38%
8.38%
Reduce
3 750.00K $102.28M 7.63%
7.63%
Add
4 1.80M $73.98M 5.52%
5.52%
Add
5 900.00K $61.64M 4.60%
4.60%
Reduce
6 750.00K $50.25M 3.75%
3.75%
Hold
7 350.00K $49.93M 3.72%
3.72%
Add
8 1.20M $48.96M 3.65%
3.65%
Reduce
9 925.00K $39.08M 2.91%
2.91%
Add
10 675.00K $37.25M 2.78%
2.78%
Add
11 2.75M $31.95M 2.38%
2.38%
Add
12 725.00K $30.37M 2.27%
2.27%
New
13 3.25M $29.57M 2.21%
2.21%
Add
14 2.30M $27.09M 2.02%
2.02%
Add
15 6.49M $26.15M 1.95%
1.95%
New
16 1.75M $25.97M 1.94%
1.94%
New
17 5.43M $25.36M 1.89%
1.89%
Add
18 300.00K $24.15M 1.80%
1.80%
New
19 560.00K $21.99M 1.64%
1.64%
New
20 1.83M $21.96M 1.64%
1.64%
Reduce
21 3.60M $21.71M 1.62%
1.62%
Add
22 4.75M $21.28M 1.59%
1.59%
Add
23 500.00K $20.77M 1.55%
1.55%
New
24 525.00K $20.47M 1.53%
1.53%
Add
25 440.00K $18.20M 1.36%
1.36%
Add
26 1.25M $17.23M 1.28%
1.28%
New
27 350.00K $16.85M 1.26%
1.26%
Reduce
28 600.00K $15.53M 1.16%
1.16%
Add
29 2.67M $15.11M 1.13%
1.13%
Add
30 840.00K $13.47M 1.00%
1.00%
Add
31 335.00K $12.85M 0.96%
0.96%
Add
32 1.00M $12.10M 0.90%
0.90%
New
33 500.00K $11.61M 0.87%
0.87%
New
34 500.00K $10.44M 0.78%
0.78%
New
35 2.10M $9.79M 0.73%
0.73%
New
36 100.00K $8.04M 0.60%
0.60%
New
37 60.00K $8.03M 0.60%
0.60%
New
38 280.00K $8.01M 0.60%
0.60%
Add
39 225.00K $7.94M 0.59%
0.59%
New
40 1.16M $7.19M 0.54%
0.54%
Add
41 620.00K $6.63M 0.49%
0.49%
Add
42 2.00M $6.56M 0.49%
0.49%
Add
43 2.20M $5.13M 0.38%
0.38%
Add
44 6.05M $4.81M 0.36%
0.36%
Add
45 600.00K $4.75M 0.35%
0.35%
Hold
46 180.00K $4.46M 0.33%
0.33%
Add
47 440.00K $3.74M 0.28%
0.28%
New
48 1.20M $3.60M 0.27%
0.27%
Hold
49 800.00K $3.40M 0.25%
0.25%
Add
50 890.00K $3.33M 0.25%
0.25%
New

FAQ

What did Vestal Point Capital, LP buy in 2024-Q2?

In its 2024-Q2 13F filing, Vestal Point Capital, LP reported 60 equity positions worth $1.34B in aggregate; its largest disclosed positions were JAZZ ($160.09M), CYTK ($112.42M), ASND ($102.28M).

How large is Vestal Point Capital, LP's portfolio?

Vestal Point Capital, LP reported $1.34B of long equity holdings across 60 positions as of 2024-Q2. Top-10 holdings account for 54.9% of reported value.

What is Vestal Point Capital, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/vestal-point-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →